LONDON: Encouraging new data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute, its makers said on Wednesday.
It also has a manufacturing advantage, he said, citing a deal with Serum Institute of India to produce 200 million doses annually, starting 2023. On Wednesday, data from a mid-stage study on more than 400 young children who received a fourth dose of the Oxford shot after the primary three-dose regimen was published in the Lancet journal.
Meanwhile, late-stage trial data published last year showed that if Mosquirix was administered ahead of peak malaria season in high transmission areas, it was nearly 63 per cent effective against clinical malaria.